coronavirus
known
five
decad
sinc
first
prototyp
murin
strain
jhm
report
virus
porcin
transmiss
gastroenter
viru
tgev
avian
infecti
bronchiti
viru
ibv
bovin
coronaviru
bcov
sever
infect
anim
murin
coronaviru
mous
hepat
viru
mhv
studi
model
human
diseas
although
studi
mechan
replic
well
pathogenesi
sever
coronavirus
activ
sinc
famili
coronavirus
receiv
much
attent
recogn
new
human
coronaviru
respons
sever
acut
respiratori
syndrom
sar
contagi
fatal
coronavirus
belong
one
two
subfamili
coronavirina
torovirina
famili
coronavirida
turn
compris
order
nidoviral
figur
classifi
four
genera
genu
divid
lineag
subgroup
sarscov
belong
betacoronaviru
group
see
figur
new
human
coronaviru
identifi
etiolog
agent
first
global
pandem
centuri
severeacut
respiratori
syndrom
sar
viru
name
sarscov
first
case
atyp
pneumonia
report
china
novemb
rapid
unexpect
spread
anoth
countri
mostli
asia
north
america
alarm
public
world
health
organ
within
month
outbreak
announc
cumul
report
emerg
caus
death
among
case
fatal
rate
worldwid
shown
tabl
incid
indic
rapidli
contagi
ill
spread
highli
interconnect
societi
sar
mainli
character
high
fever
dyspnea
lymphopenia
headach
lower
respiratori
tract
infect
concurr
gastrointestin
symptom
diarrhea
also
enorm
effort
expert
scientist
variou
countri
novel
human
coronaviru
identifi
etiolog
agent
sequenc
inform
coronaviru
polymeras
gene
along
previous
character
strain
demonstr
previous
unrecogn
coronaviru
although
sar
epidem
success
control
identif
anim
reservoir
viru
recent
report
new
viru
relat
sar
call
middl
east
respiratori
syndrom
mer
provid
strong
motiv
develop
antisar
agent
treat
potenti
fatal
respiratori
ill
recent
outbreak
mer
south
korea
alarm
public
number
patient
quarantin
report
first
patient
diagnos
mer
may
within
period
two
month
total
number
case
identifi
increas
fatal
possibl
infect
individu
subject
end
august
total
patient
infect
worldwid
viru
die
first
case
record
june
saudi
date
fda
approv
antivir
agent
treatment
sar
although
clinic
treatment
direct
toward
symptomat
relief
therefor
develop
effect
antivir
chemotherapi
sarscov
import
futur
outbreak
numer
report
public
publish
sarscov
sinc
recent
brief
review
progress
antisar
chemotherapi
howev
report
publish
substrat
select
mechan
action
sar
inhibitor
therefor
overcom
drawback
enhanc
qualit
understand
etiolog
patholog
possibl
therapeut
target
viru
comprehens
review
current
need
perspect
focus
statu
sarscov
chymotrypsinlik
proteas
inhibitor
discov
last
year
sourc
includ
laboratori
synthet
method
natur
product
virtual
screen
structurebas
molecular
dock
studi
attempt
made
provid
complet
descript
structur
featur
sar
detail
mechan
action
inhibitor
believ
perspect
compris
cumul
sourc
sarscov
inhibitor
research
understand
antisar
chemotherapi
coronavirus
famili
posit
strand
envelop
rna
virus
caus
acut
chronic
respiratori
enter
central
nervou
system
diseas
mani
speci
anim
includ
famili
featur
largest
viral
genom
kb
found
genom
rna
complex
basic
nucleocapsid
n
protein
form
helic
capsid
within
membran
membran
coronavirus
compris
minimum
three
viral
protein
spike
protein
type
glycoprotein
ii
membran
protein
span
membran
iii
envelop
protein
e
highli
hydrophob
protein
cover
entir
structur
coronaviru
figur
sarscov
genom
contain
two
open
read
frame
connect
ribosom
frame
shift
encod
two
larg
overlap
replicas
polyprotein
kda
kda
function
protein
produc
extens
proteolyt
coronavirus
util
three
proteas
proteolyt
process
sarscov
known
encod
two
proteas
includ
papainlik
cystein
proteas
plpro
chymotrypsinlik
cystein
proteas
known
proteas
enzym
also
call
main
proteas
mpro
indispens
viral
replic
infect
process
therebi
make
ideal
target
antivir
therapi
xray
crystallograph
structur
hexapeptidyl
chlromethyl
keton
cmk
inhibitor
bound
differ
ph
valu
solv
yang
et
al
see
figur
explain
sarscov
form
dimer
two
promot
denot
b
orient
almost
right
angl
figur
b
crystal
structur
sarscov
similar
compris
three
domain
domain
residu
ii
residu
contain
form
chymotrypsin
structur
wherea
domain
iii
residu
consist
mainli
figur
sarscov
cyshi
catalyt
dyad
substrat
inhibitor
bind
site
locat
cleft
domain
ii
substratebind
subsit
specif
protom
cov
proteas
confer
absolut
specif
substrat
residu
enzym
nterminu
residu
nfinger
squeez
domain
ii
iii
parent
monom
domain
ii
monom
play
import
role
dimer
format
activ
site
sarscov
dimer
highli
activ
monom
princip
kua
et
al
report
first
prepar
fulli
activ
dimer
sarscov
authent
screen
inhibitor
sarscov
prepar
peptid
substrat
fluoresc
quench
pair
benzoic
acid
dabcyl
amino
acid
edan
n
ctermini
respect
result
extrem
sensit
assay
allow
mani
potent
inhibitor
sarscov
identifi
cystein
proteas
analogu
main
picornaviru
proteas
famili
virus
also
caus
respiratori
ill
conserv
specif
within
famili
coronavirus
report
amino
acid
sequenc
leuglnser
leuglyala
prefer
sequenc
tabl
although
function
similar
cleavag
sitespecif
picornaviru
proteas
structur
similar
two
famili
sarscov
cleav
polyprotein
less
conserv
site
involv
ser
ala
gli
sequenc
appear
conserv
pattern
activ
site
sarscov
contain
creat
catalyt
dyad
cystein
function
common
nucleophil
proteolyt
process
figur
initi
step
process
deproton
cysthiol
follow
nucleophil
attack
result
anion
sulfur
substrat
carbonyl
carbon
ii
step
peptid
product
releas
amin
terminu
histidin
restor
deproton
form
iii
next
step
result
thioester
hydrolyz
iv
releas
carboxyl
acid
free
enzym
v
regener
final
step
therefor
function
signific
viral
life
cycl
make
proteas
ideal
target
develop
drug
sar
coronaviru
infect
first
xray
structur
dimer
peptid
cmk
cbzvalasnserthrleuglncmk
see
figur
inhibitor
elucid
yang
h
et
al
unexpect
bind
mode
provid
structur
explan
enter
specif
pocket
decreas
specif
sar
enzym
howev
specif
observ
structur
bound
tgev
wherea
orient
toward
bulk
solvent
addit
compound
rupintrivir
shown
figur
alreadi
clinic
test
common
cold
target
rhinoviru
proteas
bind
human
rhinoviru
proteas
orient
observ
cmk
inhibitor
tgev
xray
crystal
structur
tgev
superimpos
depict
figur
substrat
specif
picornaviru
site
similar
coronaviru
compound
propos
start
point
develop
new
sarscov
inhibitor
figur
addit
proteas
inhibitor
figur
found
high
bind
affin
toward
sarscov
well
use
three
molecul
peptidomimet
mani
medicin
chemistri
studi
focus
develop
potent
chemotherapi
method
sar
drug
design
treat
sarscov
broadli
classifi
two
type
peptid
inhibitor
mimic
natur
peptid
substrat
ii
small
moleculebas
inhibitor
obtain
modif
exist
proteas
inhibitor
virtual
screen
structurebas
molecular
dock
studi
natur
product
addit
metalconjug
inhibitor
well
miscellan
sarscov
inhibitor
also
discuss
perspect
peptidyl
peptidomimet
deriv
contain
michael
acceptor
warhead
import
class
cystein
proteas
inhibitor
gener
inhibitor
design
strategi
involv
replac
substrat
scissil
amid
bond
appropri
michael
acceptor
group
inactiv
cystein
proteas
michael
acceptor
group
depict
figur
cystein
residu
undergo
inhibitor
michael
acceptor
warhead
group
subsequ
proton
result
irrevers
inhibit
enzym
sar
studi
compound
indic
inhibitori
activ
improv
replac
follow
side
chain
residu
phenyl
group
benzyl
group
shown
figur
note
compound
two
group
could
fit
pocket
sarscov
respect
addit
isoxazol
moieti
analogu
adopt
conform
differ
inhibitor
thu
undergo
hydrogen
bond
pocket
howev
conjug
ester
access
allow
michael
addit
coval
bond
bond
format
consequ
process
achiev
subsequ
strategi
use
symmetr
analogu
figur
thu
exhibit
good
inhibitori
activ
particular
compound
compris
dipeptid
unsatur
ester
dimethylaminocinnam
acid
exhibit
potent
inhibitori
activ
valu
approxim
ki
valu
cellbas
bioassay
gave
presenc
moieti
phenyl
ring
cinnam
analogu
found
import
structur
function
activ
enhanc
anoth
seri
compound
report
base
modif
compound
side
chain
convert
pfluorobenzyl
group
smaller
benzyl
prenyl
group
inhibitor
possess
acceptor
group
coval
link
figur
result
analogu
potenti
inhibitor
sarscov
kinact
valu
effect
sarscov
cellbas
bioassay
toxic
observ
addit
observ
compound
contain
hydroxyethylen
isoster
place
ketoethylen
compound
inact
due
loss
import
hydrogen
bond
interact
backbon
amid
nitrogen
carbonyl
oxygen
inhibitor
figur
replac
unit
bocserin
prenyl
isobutyl
figur
increas
inhibitori
activ
sever
time
lead
inhibitor
confirm
group
import
structur
requir
greater
potenc
although
activ
potent
analogu
improv
sever
time
compound
sarscov
substrat
specif
site
could
identifi
inhibitori
activ
absolut
depend
residu
peptid
therefor
backbon
structur
compound
modifi
systemat
manner
report
yang
et
result
fivememb
lactam
ring
found
specif
leucin
use
show
much
better
enzym
activ
residu
tabl
strong
bind
fivememb
ring
evidenc
multipl
hydrogenbond
xray
crystal
structur
pdb
id
replac
phenylalanin
leucin
group
increas
inhibitori
activ
enzym
result
indic
rigid
planar
phenyl
ring
favor
bind
hydrophob
pocket
lipophil
tertbutyl
group
site
enhanc
bind
affin
furthermor
benzyloxi
group
found
best
replac
moieti
result
increment
enzym
inhibitori
activ
group
found
best
group
site
basi
dock
studi
benzyloxi
group
also
observ
uniqu
conform
xray
crystal
structur
dock
studi
pdb
id
see
support
inform
si
figur
novel
seri
ketoglutamin
analogu
phthalhydrazido
group
report
revers
inhibitor
sarscov
figur
discoveri
origin
due
inhibitori
activ
human
hepat
viru
compound
featur
function
adjac
keto
group
well
intramolecular
hydrogen
bond
carbonyl
make
electrophil
suscept
hemithioacet
format
activ
site
proteas
compound
recogn
potent
analogu
inhibitori
valu
sar
studi
indic
phthalhydrazid
moieti
import
good
inhibit
specif
introduct
inhibitor
contain
phthalhydrazid
moieti
greatli
enhanc
inhibitori
activ
sarscov
compar
inhibitor
vs
support
molecular
model
studi
activ
inhibitor
show
bind
via
extend
interact
residu
format
hydrogen
bond
side
chain
recent
report
disclos
xray
crystal
structur
sarscov
complex
one
phthalhydrazid
base
peptid
inhibitor
figur
pdb
id
inhibitor
form
unusu
thiiranium
ring
nucleophil
sulfur
atom
trap
enzym
catalyt
residu
configur
similar
intermedi
state
propos
exist
hydrolysi
nativ
addit
data
suggest
structur
resembl
propos
tetrahedr
intermedi
deacyl
step
normal
peptid
hydrolysi
furthermor
prove
import
phthalhydrazid
unit
inhibitor
seri
analogu
modifi
phthalhydrazid
thiophen
report
weak
activ
sarscov
divers
seri
peptid
anilid
report
base
niclosamid
figur
unlik
typic
nitroanilidebas
peptid
readili
hydrolyz
serin
cystein
peptid
effici
cleav
sarscov
niclosamid
show
inhibitori
activ
concentr
potent
inhibitor
anilid
deriv
anilin
lphenylalanin
dimethylamino
benzoic
acid
anilid
competit
inhibitor
sarscov
ki
valu
show
high
select
toward
sarscov
rather
proteas
trypsin
chymotrypsin
papain
chlorin
atom
oposit
ring
amido
group
coplanar
conform
thu
make
hydrolysi
unfavor
modif
compound
seri
analogu
result
reduc
potenc
dock
studi
figur
pdb
id
show
unit
compound
occupi
second
prefer
pocket
thu
nitro
group
predict
hydrogen
bond
provid
possibl
key
interact
catalyt
dyad
dimethylamino
phenyl
group
fit
cleft
form
dock
studi
also
suggest
anilid
lowest
bind
energi
kcalmol
compar
deriv
experi
support
observ
enzymat
assay
reveal
import
role
dimethylamino
benzoic
acid
residu
effect
report
novel
class
azapeptid
epoxid
ape
act
inhibitor
clan
cd
cystein
compound
librari
screen
compound
figur
show
promin
activ
irrevers
inhibit
sarscov
kinactki
kinet
data
crystal
structur
ape
report
lee
tw
et
al
react
sdiastereom
r
rdiastereom
addit
epoxid
atom
ape
must
sconfigur
comprehens
screen
variou
peptid
electrophil
build
blockattach
group
eg
epoxid
aziridin
identifi
potenti
inhibitor
data
reveal
aziridin
import
inhibit
transconfigur
compound
contain
glyglyaziridin
peptid
inhibit
select
modest
activesit
direct
irrevers
sarscov
inhibitor
figur
studi
also
reveal
epoxid
aziridin
build
block
alon
contain
amino
acid
moieti
activ
seri
peptid
aldehyd
librari
design
target
sar
coronaviru
base
irrevers
inhibitor
cmk
shown
possess
weak
inhibitori
activ
sar
proteas
inhibitor
cmk
bind
canon
mode
tgev
result
bind
mode
address
respect
pocket
expos
solvent
figur
howev
monom
sarscov
cmk
inhibitor
follow
differ
side
chain
orient
noncannon
bind
mode
residu
posit
respect
pocket
enzym
remain
solvent
expos
instead
associ
pocket
pocket
occupi
figur
basi
structur
find
observ
sequenti
variat
p
site
initi
structur
produc
potent
inhibitor
especi
modif
site
wherea
mutat
site
yield
moder
improv
inhibitor
peptid
acnstsqh
acestlqh
found
potent
best
revers
inhibitor
valu
low
micromolar
rang
figur
interestingli
inhibitor
assum
bind
noncanon
mode
similar
cmk
tgev
figur
addit
sar
suggest
substrat
specif
sarscov
requir
glutamin
posit
larg
hydrophob
residu
posit
moreov
xray
crystal
structur
pentapeptid
aldehyd
acestlqh
pdb
id
acnsfsqh
pdb
id
acdsfdqh
pdb
id
acnstsqh
pdb
id
complex
sarscov
reveal
pocket
enzym
accommod
serin
even
aspart
acid
side
chain
posit
see
si
figur
howev
cleavag
effici
serin
time
lower
origin
substrat
aspart
acid
cleavag
observ
furthermor
research
group
also
determin
xray
crystal
structur
sarscov
complex
cmffh
ki
see
figur
complex
structur
see
si
figur
pdb
id
compound
residu
locat
hydrophil
subsit
result
hydrophob
interact
group
cmffh
result
suggest
stringent
specif
sarscov
respect
posit
overcom
highli
electrophil
charact
aldehyd
warhead
novel
potent
sarscov
inhibitor
ki
nm
develop
antivir
agent
sarscov
human
coronaviru
hcov
replic
reduc
viral
titer
log
sarscov
log
hcov
figur
inhibitor
distinct
function
group
site
compar
refer
compound
inhibitor
design
evalu
issu
cell
viabil
stabil
druglik
properti
base
compound
accordingli
leucin
moieti
replac
bulki
cyclohexylalanin
improv
cell
activ
ester
group
replac
aldehyd
avoid
hydrolysi
esteras
result
compound
display
stabl
profil
mous
rat
human
plasma
tabl
xray
crystal
structur
pdb
id
reveal
uniqu
bind
mode
compris
coval
bond
hydrogen
bond
numer
hydrophob
interact
see
si
figur
cours
studi
sarscov
found
matur
sarscov
sensit
degrad
site
caus
loss
catalyt
activ
stabil
sarscov
dramat
increas
mutat
arg
posit
ile
enzymat
effici
mutant
increas
factor
potenc
mutant
proteas
make
possibl
quantit
evalu
substratebas
inhibitor
use
convent
highperform
liquid
chromatographi
hplc
psite
pentapeptid
sequenc
acseralavalleunhch
cho
figur
inhibit
catalyt
activ
sarscov
valu
side
chain
structur
especi
site
optim
step
step
base
xray
crystallograph
analys
complex
provid
potent
tetra
peptid
aldehyd
inhibitor
figur
new
seri
n
glutaminyl
aspart
acid
inhibitor
fluoromethyl
keton
warhead
report
sarscov
inhibitor
tabl
inhibitor
design
base
caspas
inhibitori
antivir
activ
assess
cytopath
effect
cpe
inhibit
sarscov
infect
vero
cultur
reveal
compound
effect
inhibit
strain
sarscov
replic
among
inhibitor
compound
exhibit
promis
activ
low
toxic
cell
protect
cell
valu
exhibit
select
index
addit
compound
show
low
toxic
mice
sar
studi
residu
identifi
conserv
recognit
site
sarscov
replac
n
glutamin
see
howev
compound
potent
caspas
inhibitor
acid
abolish
activ
furthermor
also
replac
isoleucin
valin
activ
compound
found
inact
rhinoviru
cellbas
assay
suggest
compound
specif
sarscov
compound
found
low
toxic
mice
administr
singl
dose
mgkg
weight
loss
behavior
chang
gross
patholog
major
organ
observ
test
dose
studi
suggest
compound
could
promis
candid
anim
efficaci
abel
et
al
propos
trifluoromethyl
keton
fmk
also
use
proteas
interest
featur
inhibitor
format
thermodynam
stabl
hemiket
hemithioket
occur
upon
nucleophil
attack
serhydroxyl
cysthiol
group
present
serin
cystein
proteas
respect
basi
observ
hayashi
et
al
report
glnderiv
keton
sarscov
inhibitor
figur
compound
show
modest
inhibitori
activ
due
format
typic
cyclic
structur
expect
interact
effect
activ
avoid
problem
side
chain
site
modifi
order
block
shown
figur
compound
show
excel
activ
optim
provid
compound
show
low
nanomolar
inhibit
sarscov
continu
explor
sar
base
fmk
inhibitor
seri
trifluoro
methyl
keton
develop
mainli
focus
posit
tabl
three
differ
amino
acid
demonstr
variabl
residu
posit
inhibitori
activ
observ
rang
potent
inhibitor
compound
possess
moieti
substrat
sequenc
peptid
site
exhibit
compar
activ
compound
shown
tabl
replac
methyl
group
hydrogen
result
loss
activ
inhibitor
show
timedepend
inhibit
ki
valu
h
previous
propos
hiv
proteas
inhibitor
could
serv
good
start
point
develop
sarscov
inhibitor
gener
revers
inhibitor
produc
fewer
side
effect
suicid
inhibitor
thu
suitabl
drug
develop
recent
compound
noncoval
hiv
proteas
inhibitor
ki
nm
use
lead
structur
optim
use
comput
analysi
develop
sarscov
shown
figur
introduct
peripher
valala
residu
place
cbz
group
introduct
group
place
phenyl
group
compound
led
format
inhibitor
potent
sarscov
inhibitor
ki
valu
respect
addit
compound
highli
select
inhibit
observ
hiv
proteas
hplcbase
screen
electrophil
compound
reveal
etacryn
acid
deriv
inhibit
ki
inhibit
ki
effect
inhibitor
sarscov
inhibitor
obtain
sequenti
modif
etacryn
acid
wellknown
diuret
also
show
activ
toward
cystein
proteas
papain
proteas
ki
ester
show
potenc
toward
papain
proteas
ki
sarscov
ki
howev
etacryn
acid
amid
ki
found
affin
toward
sarscov
sar
studi
reveal
chloro
substitu
phenyl
moieti
necessari
sarscov
inhibit
figur
compound
unsubstitut
phenyl
ring
methyl
substitu
inact
addit
quit
promis
ester
amid
display
establish
certain
isatin
compound
potent
inhibitor
rhinoviru
proteas
sarscov
rhinoviru
share
similar
activ
site
catalyt
isatin
deriv
may
also
good
candid
antisar
drug
develop
accordingli
seri
synthet
isatin
deriv
report
noncoval
sar
proteas
unlik
rhinoviru
coval
bond
bind
mode
tabl
isatin
deriv
inhibit
sarscov
low
micromolar
rang
inhibitor
found
potent
sar
studi
reveal
inhibitori
potenc
heavili
depend
hydrophob
electron
affin
substitu
isatin
core
moreov
comput
analysi
dock
studi
pdb
id
see
si
figur
activ
compound
show
fit
well
activ
pocket
sarscov
two
carbonyl
group
isatin
could
form
hydrogen
bond
interact
nh
group
side
chain
addit
compound
exhibit
better
select
sar
proteas
includ
papain
chymotrypsin
mm
trypsin
chemotherapeut
agent
target
viral
entri
import
class
antivir
therapi
block
propag
viru
earli
stage
thu
minim
chanc
viru
evolv
acquir
drug
resist
screen
chines
herbal
medicinebas
molecul
result
discoveri
luteolin
inhibitor
wildtyp
sarscov
activ
effect
concentr
figur
compound
identifi
activ
use
twostep
screen
method
consist
frontal
affin
spectrometri
coupl
viral
infect
assay
base
human
immunodefici
viru
hiv
lucsar
pseudotyp
viru
flavon
analogu
bind
surfac
spike
protein
sarscov
thu
interfer
entri
viru
host
cell
howev
relat
flavon
quercetin
deriv
exhibit
modest
inhibitori
activ
sar
viru
figur
identifi
potenti
inhibitor
sarscov
show
inhibitori
activ
sprfretbas
enzymat
inhibit
dock
studi
sarscov
suggest
residu
play
key
role
bind
interact
confirm
predict
bind
mode
compar
wildtyp
sarscov
mutat
sarscov
compar
studi
consist
dock
predict
inhibitori
potenc
sarscov
significantli
decreas
besid
experiment
evid
show
enzymat
activ
sarscov
affect
mutat
lfucos
deriv
exhibit
potent
inhibitori
activ
compar
sar
molecular
dock
studi
new
deriv
reveal
four
hydroxi
group
quercetin
moieti
key
determin
potenti
biolog
activ
part
ongo
investig
bioflavonoid
medicin
plant
potenti
sarscov
inhibitor
seri
inhibitor
report
leav
torreya
nucifera
figur
among
isol
compound
biflavon
amentoflavon
recogn
potent
noncompetit
inhibitor
exhibit
valu
sar
studi
demonstr
three
authent
flavon
apigenin
luteolin
quercetin
show
inhibitori
activ
respect
activ
amentoflavon
consist
bind
interact
dock
studi
pdb
id
see
si
figur
one
key
bind
mode
target
site
moreov
bind
energi
differ
apigenin
kcalmol
amentoflavon
kcalmol
consist
lower
valu
toward
sarscov
apigenin
seri
diterpenoid
torreya
nucifera
evalu
antisar
activ
figur
howev
terpenoid
exhibit
low
activ
compar
biflavonoid
sarscov
concentr
one
except
ferruginol
exhibit
significantli
greater
activ
moreov
quinonemethid
triterpenoid
celastrol
pritimererin
tingenon
iguesterin
isol
methanol
extract
tripterygium
regelii
celastracea
show
moder
inhibitori
activ
valu
respect
wherea
correspond
semisynthet
analogu
dihydrocelastrol
reduc
inhibitori
potenc
figur
sar
studi
suggest
moieti
ring
hydrophob
ere
assist
produc
potent
inhibitori
activ
compound
mention
proven
competit
inhibitor
use
kinet
analysi
furthermor
abietanetyp
diterpenoid
lignoid
exhibit
strong
antisarscov
particular
betulin
acid
savinin
shown
act
competit
inhibitor
sarscov
ki
valu
respect
figur
basi
molecular
model
analysi
observ
competit
inhibit
sarscov
activ
consist
format
multipl
hydrogen
bond
interact
compound
specif
amino
acid
residu
locat
activ
site
pocket
proteas
enzym
structurebas
virtual
screen
chemic
databas
contain
compound
sarscov
inhibit
produc
two
hit
sulfon
dihydroimidazol
figur
core
structur
two
hit
defin
molecular
dock
studi
use
search
analogu
accordingli
analogu
deriv
two
hit
exhibit
valu
two
potent
compound
obtain
hit
show
valu
furthermor
combin
structurebas
virtual
screen
threedimension
quantit
relationship
studi
compound
databas
compound
led
identif
compound
exhibit
modest
inhibit
valu
respect
figur
basi
analysi
common
core
structur
acetamid
identifi
potenti
bind
mode
compound
predict
molecular
model
studi
dock
studi
pdb
id
see
si
figur
strong
interact
benzen
thiazol
unit
sarscov
activ
site
could
explain
increas
potenc
wong
report
novel
class
mechanismbas
irrevers
inhibitor
activ
nanomolar
rang
use
combinatori
synthesi
microtit
plate
follow
situ
instead
expect
amid
reaction
product
seri
benzotriazol
ester
isol
surprisingli
inhibitori
activ
analogu
much
higher
small
molecul
peptidomimet
sar
optim
yield
analogu
nanomolar
inhibitori
activ
figur
interest
point
found
ester
deriv
benzoic
acidcontain
electron
withdraw
substitu
eg
cn
suscept
hydrolysi
wherea
ester
electrondon
substitu
rel
stabl
ph
solut
h
room
temperatur
compound
ki
nm
potent
among
benzotriazol
possibl
mode
action
could
acyl
activ
site
assist
catalyt
dyad
irrevers
enzym
acyl
verifi
electrospray
ioniz
mass
spectrometri
inhibit
enzym
compound
figur
addit
recent
xray
crystal
structur
sarscov
complex
benzotriazol
ester
also
confirm
activesit
cystein
acyl
ester
ligand
act
suicid
note
format
nhydroxybenzotriazol
potent
inhibitor
enzym
heteroaromat
ester
also
identifi
potent
inhibitor
sar
moieti
compound
prove
key
unit
activ
sarscov
continu
sar
studi
provid
potent
inhibitor
inhibitori
activ
span
micromolar
nanomolar
rang
structur
biolog
analysi
suggest
addit
halopyridyl
unit
aromat
ring
also
key
factor
potent
inhibit
figur
coval
bond
format
mechan
complex
propos
basi
electrospray
mass
spectrometri
investig
figur
howev
anoth
strategi
demonstr
combin
key
part
previous
mention
mechanismbas
inhibitor
produc
novel
seri
indolecarboxyl
inhibitor
enzymat
potenc
submicromolar
rang
figur
sar
studi
suggest
posit
carboxyl
acid
ester
free
indol
hydrogen
nh
critic
activ
indol
carboxyl
carboxyl
function
posit
potent
inhibitor
enzym
inhibitori
activ
nm
antivir
valu
ester
describ
previou
section
act
highli
potent
inhibitor
sarscov
valu
low
nanomolar
rang
initi
bind
competit
strongli
activ
site
hydrolyz
enzym
substrat
releas
despit
potent
inhibit
sarscov
rel
long
halflif
buffer
neutral
ph
valu
like
problemat
drug
candid
due
propens
rapidli
hydrolyz
lipas
esteras
enzym
mammalian
cell
moreov
compound
also
potenti
react
nonspecif
thiol
nucleophil
mammalian
cell
therebi
lead
toxic
therefor
develop
stabl
noncoval
inhibitor
base
pyridinyl
ester
group
methylen
keton
correspond
mono
difluorin
methylen
keton
report
sarscov
inhibitor
zhang
j
et
al
figur
compound
show
best
inhibit
specif
inhibitor
potent
among
analogu
molecular
model
studi
activ
keton
analogu
predict
bind
conform
similar
correspond
pyridinyl
sar
studi
suggest
fluorin
decreas
inhibit
despit
enhanc
electrophil
carbonyl
carbon
enzymat
analysi
esim
studi
indic
inhibitor
util
noncoval
revers
mechan
action
high
throughput
screen
identifi
tetrasubstitut
pyrazol
display
substitut
pattern
sarscov
inhibitor
explor
sar
produc
seri
pyrazolon
demonstr
inhibitori
activ
sarscov
figur
among
compound
exhibit
potent
inhibitori
activ
valu
respect
analysi
indic
ring
attach
pyrazolon
accompani
electron
withdraw
group
cn
f
favor
inhibitori
activ
molecular
model
studi
activ
compound
predict
group
locat
pocket
carboxyl
benzyliden
group
pocket
crucial
inhibitori
activ
pyrimidin
deriv
design
antisar
activ
report
figur
compound
potent
inhibitor
show
enzym
inhibitori
activ
sarscov
sar
studi
reveal
presenc
nitro
function
posit
benzyliden
ring
import
activ
enhanc
potent
activ
consist
molecular
dock
studi
dock
studi
pdb
id
see
si
figur
oxygen
nitro
group
form
hydrogen
bond
side
chain
addit
phenyl
ring
predict
fit
pocket
due
hydrophob
inter
action
start
peptid
inhibitor
see
section
novel
nonpeptid
decahydroisoquinolin
inhibitor
design
synthes
base
cleavag
site
interact
hydrophob
interact
site
sar
sarscov
decahydroisoquinolin
inhibitor
figur
show
weak
inhibitori
activ
sarscov
confirm
fuse
ring
structur
decahydroisoquinolin
scaffold
accommod
activ
site
sarscov
xray
crystallograph
studi
pdb
id
confirm
decahydroisoquinolin
inhibitor
activ
site
cleft
observ
inhibitor
decahydroisoquinolin
scaffold
insert
larg
pocket
occupi
pocket
site
imidazol
insert
pocket
expect
interact
effect
hold
termin
aldehyd
tightli
insid
activ
site
cleft
result
compact
fit
novel
scaffold
sarscov
jacob
et
al
conduct
highthroughput
screen
nih
molecular
librari
compound
evalu
inhibit
mediat
peptid
cleavag
use
novel
fretbas
screen
dipeptid
class
repres
hit
figur
identifi
optim
studi
base
deriv
ugi
librari
structur
relat
hit
compound
result
seri
inhibitor
among
two
compound
figur
shown
activ
sarscov
xray
crystal
structur
bound
sarscov
figur
demonstr
bind
orient
similar
known
coval
peptidomimet
inhibitor
exampl
compound
preferenti
occupi
subpocket
sarscov
enzym
renantiom
tertbutyl
amid
occupi
tertbutylanilido
group
occupi
deep
moieti
occupi
furyl
amid
act
group
inhibitor
lack
reactiv
warhead
basi
sar
relat
analogu
first
chemic
librari
focus
exclus
group
synthes
hold
group
constant
result
seri
sar
studi
around
show
fivememb
heterocycl
prove
success
figur
especi
compound
bear
imidazol
analogu
exhibit
equipot
valu
respect
next
unit
replac
isoster
order
identifi
altern
hydrogen
bond
acceptor
group
effort
led
identifi
anoth
set
compound
figur
among
pyridazin
pyrazin
toler
although
improv
found
around
pyridyl
ring
analogu
toler
reduc
continu
studi
racem
compound
purifi
chiral
supercrit
fluid
chromatographi
separ
r
enantiom
figur
evalu
compound
r
exhibit
inhibitori
activ
sarscov
enantiom
inact
mechan
inhibit
sarscov
r
determin
competit
ki
noncoval
inhibit
owe
excel
inhibit
antivir
activ
mockinfect
sarscov
infect
vero
cell
r
elect
first
class
probe
candid
furyl
amid
follow
identif
probe
compound
r
research
group
continu
effort
develop
potent
noncoval
sarscov
inhibitor
base
upon
chemic
class
benzotriazol
mlpcn
result
hit
compound
figur
demonstr
sarscov
good
select
versu
plpro
xray
crystal
structur
bound
sarscov
show
diamid
bind
inducedfit
bind
site
form
rearrang
residu
side
chain
pdb
id
figur
induc
fit
site
accommod
synnmethyl
pyrrol
anilido
acetamid
moieti
inhibitor
within
subpocket
character
subpocket
respect
figur
schemat
illustr
inhibitoract
site
interact
orient
similar
manner
depict
figur
improv
activ
first
sar
studi
focus
benzotriazol
replac
altern
hydrogen
bond
acceptor
function
demonstr
result
replac
benzotriazol
figur
toler
second
acetamid
modif
region
seri
cyclic
acycl
congen
yield
mani
inhibitor
show
activ
figur
specif
branch
ipropyl
deriv
cyclobutylamid
greatest
activ
third
research
turn
minimum
pharmacophor
reduc
overal
molecular
weight
effort
led
seri
analogu
sar
prove
truncat
amid
figur
compar
activ
versu
elabor
amid
exampl
compar
vs
compound
repres
first
nm
inhibitor
seri
one
potent
nonwarhead
base
sarscov
inhibitor
date
compound
one
potent
inhibitor
select
probe
biolog
profil
inhibitor
r
indic
figur
rel
probe
r
equipot
diamid
compound
prove
offer
progress
sever
area
inhibitor
amu
lower
mw
mw
rel
moder
ligand
effici
le
moder
clogp
valu
clogp
greatli
improv
ligand
efficiencydepend
lipophil
lelp
versu
r
probe
r
test
inhous
vitro
dmpk
panel
includ
plasma
protein
bind
enzym
inhibit
intrins
clearanc
use
liver
microsom
r
possess
good
free
fraction
howev
intrins
clearanc
indic
r
predict
highli
clear
r
possess
modest
enzym
inhibit
maintain
activ
across
four
major
cyp
enzym
see
figur
probe
found
highli
select
eurofin
leadprofil
modest
activ
melatonin
receptor
radioligand
bind
assay
metal
ion
shown
inhibit
mani
viral
proteas
norovirus
papainlik
proteas
sarscov
human
cytomegaloviru
hcmv
proteas
hepat
c
viru
hcv
screen
metal
conjug
compound
allow
inhibitor
potent
inhibitori
activ
sarscov
identifi
includ
competit
inhibitor
phenyl
mercur
acet
ki
thimeros
ki
phenyl
mercur
nitrat
ki
figur
howev
inhibit
pronounc
use
zincconjug
compound
ie
zinc
ki
compar
ion
alon
ki
xray
crystal
structur
sarscov
pdb
id
reveal
phenylbound
mercuri
occupi
pocket
respons
enzymat
activ
hg
ii
ion
known
caus
toxic
effect
affin
ion
thiol
group
protein
lead
nonspecif
inhibit
cellular
howev
regard
structur
zinccent
complex
zinc
ion
play
key
role
target
catalyt
residu
via
bind
catalyt
dyad
yield
zinc
central
tetrahedr
geometri
type
inhibit
similar
zincmedi
serin
proteas
inhibitor
trypsin
zinc
ion
coordin
two
chelat
nitrogen
atom
bi
methan
babim
two
catalyt
residu
hisser
trypsin
tetrahedr
safeti
zinccontain
compound
human
use
indic
fact
zinc
acet
zinc
sulfat
ad
supplement
drug
treatment
wilson
diseas
behcet
diseas
moreov
possibl
zinc
complex
incorpor
cell
cell
membran
also
demonstr
studi
diabet
analysi
activ
site
caviti
proteas
reveal
presenc
subsit
contain
cluster
serin
residu
attract
target
design
high
affin
small
molecul
inhibitor
cluster
conserv
known
coronaviru
proteas
particular
conserv
known
coronaviru
known
potenti
reactiv
boron
acid
compound
hydroxyl
group
serin
residu
seri
bifunct
boron
acidconjug
compound
report
sarscov
enzym
figur
greatest
improv
affin
achiev
amid
type
compound
ki
nm
isotherm
titrat
microcalorimetr
experi
indic
inhibitor
bind
revers
sarscov
enthalp
favor
manner
impli
establish
strong
interact
proteas
molecul
past
decad
silico
virtual
screen
vs
particular
structurebas
virtual
screen
sbv
emerg
reliabl
costeffect
timesav
techniqu
discoveri
lead
compound
altern
high
throughput
screen
htp
applic
vs
discoveri
new
enzym
inhibitor
involv
dock
comput
fit
compound
structur
activ
site
enzym
score
rank
basi
structur
inform
structur
divers
small
molecul
screen
genometodruglead
approach
compound
show
modest
activ
target
human
sarscov
figur
virtual
screen
structur
divers
small
molecul
allow
compound
antisarscov
activ
inhibitor
show
potent
inhibitori
activ
valu
vero
cellbas
sarscov
plaqu
reduct
assay
figur
anoth
group
research
use
quench
fluoresc
reson
energi
transfer
assay
screen
druglik
molecul
result
appli
seri
virtual
experiment
filter
five
structur
novel
molecul
identifi
show
potent
inhibitori
activ
sarscov
among
compound
figur
show
good
inhibitori
activ
sarscov
exhibit
interest
select
inhibit
proteas
test
hav
chymotrypsin
papain
elucid
crystal
structur
sarscov
provid
enorm
opportun
discoveri
inhibitor
ration
drug
design
part
effort
discov
small
molecul
inhibitor
sarscov
structurebas
virtual
screen
small
molecul
screen
sarscov
use
knowledgebas
filter
yield
molecul
followup
biolog
evalu
inhibitor
low
micromolar
rang
found
two
compound
valu
respect
figur
report
sever
nucleosid
deriv
nucleobas
show
potent
antivir
activ
type
analogu
known
inhibit
bacteri
rna
polymeras
seri
nucleosid
analogu
evalu
antisarscov
activ
plaqu
reduct
among
two
compound
exhibit
modest
antisarscov
activ
valu
respect
compar
mizoribin
ribavirin
figur
studi
reveal
sever
sar
trend
moieti
protect
benzyl
group
respons
potent
inhibitori
activ
ribavirin
broadspectrum
inhibitor
rna
dna
virus
use
treatment
sar
affect
inhibit
viral
growth
concentr
attain
human
serum
contrast
interferon
ifn
show
vitro
inhibitori
effect
concentr
interestingli
combin
ribavirin
synergist
inhibit
sarscov
replic
hiv
proteas
inhibitor
antimalari
agent
show
strong
inhibitori
activ
sarscov
replic
howev
cytoprotect
effect
found
nelfinavir
independ
structurebas
virtual
screen
compound
conduct
identifi
novel
sarscov
toprank
compound
free
bind
energi
rang
kcal
select
evalu
hydrogen
bond
interact
activ
site
sarscov
among
compound
select
inhibitori
activ
toward
sarscov
escherichia
coli
two
compound
demonstr
competit
inhibitor
ki
valu
respect
figur
detail
dock
simul
analys
suggest
inhibitor
could
stabil
format
hydrogen
bond
catalyt
residu
establish
hydrophob
contact
opposit
region
activ
site
particular
potent
compound
nitrophenyl
group
like
crucial
sarscov
inhibitori
activ
format
hbond
well
hydrophob
interact
recent
combin
virtual
screen
vs
highthroughput
screen
ht
techniqu
appli
screen
compound
structur
divers
librari
allow
novel
nonpeptid
small
molecul
inhibitor
human
sarscov
identifi
figur
newli
identifi
compound
low
molecular
weight
examin
select
three
proteas
name
sarscov
plpro
cystein
proteas
human
cystein
proteas
hepat
c
viru
serin
proteas
two
nonproteolyt
enzym
bacillu
anthraci
dihydroorotas
streptococcu
pneumonia
purc
compound
display
good
select
sarscov
show
inhibitori
activ
five
enzym
wherea
compound
show
select
two
sar
cystein
proteas
plpro
enzym
low
molecular
weight
compound
typic
lack
high
specif
lack
inhibit
compound
enzym
especi
cystein
proteas
particularli
noteworthi
emerg
sar
identif
coronaviru
caus
agent
diseas
astound
coronaviru
commun
first
definit
associ
coronaviru
sever
diseas
human
first
crystal
structur
sarscov
dimer
peptid
cmk
inhibitor
coval
bound
elucid
crystal
structur
enzym
report
structurebas
design
virtual
screen
provid
peptidomimet
nonpeptidomimet
inhibitor
potenc
micromolar
nanomolar
rang
yet
date
effect
therapi
treatment
sar
human
knowledg
cov
inhibitor
taken
clinic
develop
perspect
describ
sar
sever
class
inhibitor
highlight
structur
featur
bind
mode
peptidomimet
small
molecul
sarscov
larg
base
warheadbas
design
strategi
far
inhibitor
describ
exhibit
good
enzymat
cellular
potenc
major
inhibitor
follow
addit
studi
antivir
activ
vivo
evalu
like
due
unattract
structur
andor
nonid
physiochem
properti
reactiv
warhead
group
use
peptidomimet
inhibitor
sarscov
includ
michael
acceptor
aldehyd
epoxi
keton
electrophil
keton
halomethyl
keton
trifluoromethyl
keton
although
peptidomimet
coval
inhibitor
potenti
toxic
signific
improv
made
enzymat
cellular
potenc
mani
peptidomimet
inhibitor
describ
literatur
highlight
figur
appear
promis
optim
effort
compound
figur
exampl
inhibitor
incorpor
michael
acceptor
develop
pfizer
inhibitor
human
rhinoviru
proteas
common
cold
target
rhinoviru
although
activ
sarscov
cell
cultur
serv
good
start
point
antisar
drug
design
lead
inhibitor
see
section
two
potent
inhibitor
sarscov
incorpor
michael
acceptor
warhead
specif
compound
exhibit
excel
cellular
potenc
valu
nontox
antisar
agent
howev
vivo
studi
compound
report
literatur
peptid
aldehyd
promis
enzymat
inhibitor
unlik
effect
therapeut
agent
due
rapid
vivo
metabol
low
oral
bioavail
contrast
peptid
aldehyd
thrombin
inhibitor
efegatran
well
toler
phase
clinic
inhibitor
potent
peptid
aldehyd
show
remark
activ
sarscov
human
coronaviru
hcov
replic
reduc
viral
titer
log
sarscov
log
hcov
inhibitor
also
display
stabl
profil
mous
rat
human
plasma
see
section
may
repres
start
point
develop
antisar
agent
inhibitor
one
potent
inhibitor
halomethyl
seri
exhibit
low
toxic
mice
singl
ip
dose
mgkg
weight
loss
behavior
chang
gross
patholog
major
organ
observ
test
dose
see
section
low
molecular
weight
potenti
advantag
peptidyl
monofluoromethyl
keton
shown
effect
inhibitor
may
suitabl
candid
vivo
efficaci
toxicolog
studi
numer
small
molecul
also
discuss
perspect
major
effort
develop
nonpeptid
sarscov
inhibitor
also
reli
warheadbas
design
strategi
sever
nonpeptid
inhibitor
achiev
nanomolar
potenc
interest
inhibitor
illustr
figur
case
pyridyl
ester
potent
mechanismbas
enzym
inactiv
see
section
achiev
cellbas
inhibit
sarscov
infect
vero
cell
compound
r
promis
exampl
noncoval
sarscov
inhibitor
moder
molecular
weight
good
enzymat
antivir
activ
see
section
inhibitor
potenti
start
point
design
potent
inhibitor
noncoval
mechan
action
howev
vivo
studi
abovement
small
molecul
report
far
although
mani
structur
nonstructur
protein
known
potenti
target
anticoronaviru
therapi
none
wellconserv
due
possibl
role
viral
life
cycl
thu
limit
potenti
success
widespectrum
inhibitor
contrast
coronaviru
highli
conserv
among
coronavirus
make
attract
target
broadspectrum
inhibitor
see
si
tabl
proteas
share
sequenc
ident
sequenc
similar
therefor
target
sarscov
import
approach
develop
antivir
therapi
appli
broad
viral
infect
recent
report
reveal
mani
sarscov
inhibitor
show
potenti
activ
recent
outbreak
feasibl
rapid
advanc
drug
discoveri
develop
effect
chemotherapeut
sarscov
might
achiev
repurpos
exist
clinic
approv
drug
recent
report
screen
librari
drug
either
clinic
develop
welldefin
cellular
pathway
differ
class
therapeut
produc
seri
compound
good
activ
drug
inhibit
cov
includ
neurotransmitt
inhibitor
estrogen
receptor
antagonist
kinas
signal
inhibitor
proteinprocess
inhibitor
inhibitor
lipid
sterol
metabol
inhibitor
dna
synthesi
pair
howev
inhibitor
peptidomimet
nonpeptidomimet
target
serin
proteas
eg
hcv
proteas
thrombin
cystein
proteas
eg
calpain
cathepsin
k
caspas
test
exampl
ketoamid
calpain
nitril
cathepsin
k
dipeptidyl
phenyloxymethyl
keton
caspas
fuse
triazol
deriv
nonpeptid
factor
xa
beta
lactam
penicillin
bind
protein
therefor
structur
type
consid
futur
develop
antisar
therapi
nfinger
residu
nfinger
sar
play
import
role
enzym
dimer
therefor
peptid
ntermin
amino
acid
sequenc
may
act
inhibitor
dimer
similar
hiv
proteas
viral
wei
et
al
report
ntermin
octapeptid
ki
mm
first
exampl
inhibitor
target
dimer
interfac
sar
provid
novel
strategi
drug
design
sar
coronavirus
howev
peptidomimet
small
molecul
inhibitor
yet
report
literatur
although
would
great
challeng
explor
new
inhibitor
dimer
current
develop
comput
approach
structurebas
design
novel
inhibitor
may
success
conclus
although
huge
effort
taken
academia
pharmaceut
industri
coronaviru
proteas
inhibitor
yet
success
complet
preclin
develop
program
hope
perspect
use
medicin
chemist
target
identifi
novel
antisar
cov
inhibitor
druglik
properti
effect
therapi
coronavirus
discov
